Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Detection of misfolded tau proteins

A misfolded protein technology, applied in the field of detection of misfolded TAU proteins, can solve impractical problems

Active Publication Date: 2022-07-29
安培里翁公司 +6
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In conclusion, RT-QuiC analysis is generally ineffective and impractical for 4R tauopathies including 4R predominant and 4R+3R mixed tauopathies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Detection of misfolded tau proteins
  • Detection of misfolded tau proteins
  • Detection of misfolded tau proteins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0149] Example 1: Preparation of synthetic Aβ oligomers

[0150] Aβ1-42 was synthesized using solid-phase N-tert-butoxycarbonyl chemistry at the W. Keck facility at Yale University and purified by reverse-phase HPLC. The final product was lyophilized and characterized by amino acid analysis and mass spectrometry. To prepare stock solutions of aggregate-free, misfolded A[beta] protein, aggregates were dissolved at high pH and filtered through a 30 kDa cut-off filter to remove residual aggregates. To prepare different types of aggregates, unseeded A[beta]1-42 (10 [mu]M) solutions were incubated at 25[deg.]C, 0.1 M Tris-HCL, pH 7.4 at various times with stirring. The preparations included A[beta] monomers and a mixture of fibrils, protofibrils and soluble misfolded A[beta] protein in varying proportions depending on the incubation time. The extent of aggregation was characterized by ThT fluorescence emission, electron microscopy after negative staining, dot blot studies with A1...

Embodiment 2

[0153] Example 2: Aβ-PMCA detection and synthesis of Aβ oligomers

[0154] Example 2A. Seeding of Aβ aggregates by using or without varying amounts of synthetic soluble misfolded Aβ protein in the presence of Thioflavin T (control (no Aβ oligomers); or 3 of the synthetic soluble misfolded Aβ proteins, 80, 300, and 8400 femtomoles) were incubated with seed-free Aβ1-42 solutions to study. Aβ-PMCA general procedure: A solution of 2 μM aggregate-free Aβ1-42 in 0.1 M Tris-HCL pH7.4 (total volume 200 μL) was placed in an opaque 96-well plate and incubated alone or in the synthesis of Aβ aggregates ( Prepared by incubating for 5 h as described in Example 1) or in the presence of a 40 μL aliquot of CSF. Samples were incubated in the presence of 5 μM Thioflavin T (ThT) at a constant temperature of 22°C with cyclic agitation (1 min at 500 RPM, then 29 min without shaking) using an Eppendorf thermomixer. At various time points, ThT fluorescence was measured in 485 nm plates after excit...

Embodiment 2B

[0155] Example 2B: An amplification cycle was employed that combined phases of incubation and physical disruption. Figure 2AThe samples were incubated with cyclic agitation (1 minute at 500 RPM, then 29 minutes without shaking). Aggregation was measured over time by the binding of Thioflavin T (ThT) to amyloid fibrils using a flat plate spectrofluorometer (excitation: 435; emission: 485 nm). The graph shows the mean and standard error of 3 replicates. The concentration of Aβ oligomers was estimated assuming an average molecular weight of 170 kDa. Figure 2B is a graph showing the formation of cyclically accelerated amplified amyloid protein as measured by ThT fluorescence as a function of time from seeding with various concentrations of the synthetic soluble oligomeric A[beta] protein of Example 1. Under these conditions, aggregation of monomeric Aβ1-42 protein induced with 8400, 300, 80 and 3 fmol of synthetic soluble misfolded Aβ protein was faster and more easily disting...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods and kits are provided for amplifying and detecting misfolded tau protein from a sample, eg, from a patient suffering from Alzheimer's disease, progressive supranuclear palsy, and the like.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims priority to US Provisional Patent Application No. 62 / 507,166, filed May 16, 2017, the entire contents of which are incorporated herein by reference. Background technique [0003] Tauopathies can include, for example, Alzheimer's disease (AD), Parkinson's disease (PD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), corticobasal degeneration (CBD), Mild cognitive impairment (MCI), psoriasis (AgD), traumatic brain injury (TBI), chronic traumatic brain injury (CTE) and boxer dementia (DP), etc. Misfolded tau aggregates and fibrils can form and accumulate through nucleation and growth. Misfolded tau aggregates may cause cellular dysfunction and tissue damage, among other effects. [0004] Real-time shock-induced transformation (RT-QuiC) has been shown to cause replication of the 3-repeat (3R) tau isoform in brain homogenates and cerebrospinal fluid samples drawn from subjects wit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/48G01N33/50G01N33/68
CPCG01N2800/2821G01N33/6896G01N2333/4709G01N2333/47
Inventor 克劳迪奥·索托-贾拉罗素·M·莱博维兹贝内迪克特·K·沃尔拉特穆罕默德·沙纳瓦兹尼古拉斯·门德斯·迪纳马卡
Owner 安培里翁公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com